Publication | Open Access

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

First-line TherapyOncologyMulticenter Phase 2PharmacologyClinical TrialsImmune Checkpoint InhibitorBronchial NeoplasmPharmacotherapyCancer TreatmentExtensive-disease-small-cell Lung CancerMedicineLung Cancer